Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q4 2020 · 10-K
Revenue$69.99M$69.99M+159.2% vs Q4 2019 Net Income$5.76M$5.76MN/M vs Q4 2019 EPS Diluted$0.35$0.35N/M vs Q4 2019 Operating Incomederived$22,865,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
Operating Cash Flowderived$537,000N/M Free Cash Flowderived-$1,093,000— Margins · derivedOperating margin32.7%+70.4 pt vs Q4 2019
Net margin8.2%+35.5 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 24, 2021 · 55 d after period end